SYH2053injection
Phase 3Small molecule
SYH2053injection is one of 6 small molecule programs targeting Familial Hypercholesterolemia. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
7 competitors in Familial Hypercholesterolemia
#DrugCompanyPhaseTrials
1Niacor
AbbVieApproved
Leqvio
NovartisPhase 3
QLC7401
Qilu Pharmaceutical Co., Ltd.Phase 3
SYH2053injection
CCSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Phase 3
Atorvastatin Calcium
Merck & Co.Preclinical
YOLT-101
RRenJi Hospital
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Familial Hypercholesterolemia1 trial
A Study to Evaluate the Safety, Efficacy of SYH2053 as Monotherapy in Chinese Participants With Non-familial Hypercholesterolemia or Mixed Hyperlipidemia
Not yet recruiting·CCSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.·Phase 3·NCT07421297·760 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SYH2053injection. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details